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Abstract
Background & Aims. Chronic immunosuppression is associated with increased and more severe 
viral infections. However, little is known about the association between immunosuppression and 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to 
describe the clinical course of immunosuppressed autoimmune hepatitis (AIH) patients during 
coronavirus disease 2019 (COVID-19) infection in Italy.
Methods. Our study is a case series of AIH patients treated with immunosuppression, who tested 
positive for SARS-CoV-2 in March 2020 during outbreak of COVID-19.  
Results: Ten patients from six different hospitals in Italy were diagnosed with COVID-19 during 
the outbreak of SARS-CoV-2 in March 2020. Seven subjects were female (70%) and age ranged 
from 27 to 73 years. Before the onset of SARS-CoV-2 infection, all patients were taking 
immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other 
patients had recent acute onset of their AIH, and were consequently started high-dose steroids, as 
per induction protocol. All patients had a respiratory syndrome and had a positive nasal swab for 
SARS-CoV-2. Five patients developed a CT-confirmed COVID-19 pneumonia. Six subjects 
received a combination of antiretroviral and antimalarial drugs. In seven patients the dosage of 
immunosuppressive medication was changed. Liver enzymes were repeated during SARS-CoV-2 
infection in all hospitalized cases; they remained within the normal range in all cases, and 
improved in the two acute cases treated with high-dose steroids. The clinical outcome was 
comparable to the reported cases occurring in non-immunosuppressed subjects. 
Conclusion: Patients under immunosuppressive therapy for AIH developing COVID-19 show a 
disease course presumptively similar to that reported in non-immunosuppressed population. These 
data might help medical decision when dealing with SARS-CoV-2 infection in 
immunocompromised patients.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic infection causing 
coronavirus disease 2019 (COVID-19), and Italy is one of the mostly affected countries 
worldwide(1). The impact of COVID-19 in patients with autoimmune liver disease treated with 
immunosuppressive therapy have not been described so far. Mainly, concerns have been raised for 
immunosuppressed patients, particularly those with autoimmune hepatitis (AIH), due to the 
possibility of decompensation of liver disease, or to an unfavorable course of SARS-CoV-2 A
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infection. AIH is a rare liver disease and a prototypical example of chronic autoimmune condition 
requiring maintenance immunosuppression(2). Stopping immunosuppression is associated with 
almost inevitable relapse of the disease(3). Viral infections in immunocompromised host are more 
frequent than in the general population, and have the ability to cause severe disease at much higher 
rates than in the healthy population(4,5). Nonetheless, data from previous outbreaks of 
Coronaviruses infections, like severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS), did not report a higher risk of morbidity and mortality related to 
immunosuppression(6). Therefore, there is uncertainty on how to manage immunosuppression 
therapy during SARS-CoV-2 pandemic.
This report describes the clinical course of ten AIH patients who developed COVID-19 in Italy.  
Patients provided informed consent for the inclusion in this study, and the diagnostic procedures 
were conducted in accordance with institutional guidelines.
Case series
We contacted 67 large Italian liver units (24 in Lombardy) during the outbreak of SARS-CoV-2 
asking about cases of COVID-19 occurred in patients with AIH followed-up at these centers. 
Ten patients with AIH from seven different hospitals in Italy, mainly located in Lombardy Region, 
were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020 (Table). 
Seven subjects were female (70%) and age ranged from 27 to 73 years. Cirrhosis was present in 
four cases (40%) and patient 6 had decompensated cirrhosis (Child-Pugh B), with history of 
previous episodes of ascites and hepatic encephalopathy.
Before the onset of COVID-19, all patients were taking immunosuppressive therapy with different 
dosages: all but one (patient 8) were on steroids (prednisone), and four (40%) were on 
azathioprine; patient 1 was on triple immunosuppressive regimen due to difficult-to-treat AIH. 
The immunosuppression regimen was stable in eight patients who were on biochemical remission 
at recent evaluation. Two other patients (patient 2 and 4) had an acute onset of AIH and were 
under high-dose steroids, as per induction protocol, at the time of SARS-CoV-2 infection.
All cases were symptomatic for respiratory syndrome and positive for SARS-CoV-2 at nasal 
swab; four cases were managed at home under compulsory quarantine. Among those managed at A
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home, one patient was afebrile, had persistent cough and headache; the others were febrile and had 
cough as main symptom. Among the six hospitalized subjects, five developed a CT-confirmed 
COVID-19 pneumonia. Three patients were treated with continuous positive airway pressure 
support for hypoxemic respiratory failure. 
All subjects received a combination of an antiretroviral drug (either lopinavir/ritonavir or 
darunavir/cobicistat) with an antimalarial medication (either hydroxychloroquine or chloroquine); 
two cases were also treated with azithromicine. Empirical therapies for SARS-CoV-2 infection 
were in line with recommendations given by the infectious disease service of each hospital. 
In seven patients the dosage of immunosuppressive therapy was changed. Prednisone regimens 
were heterogeneously managed: in three cases doses were reduced, while Patient 9 self-stopped it. 
Patient 2 and 4 were given high dose corticosteroids to induce remission and tapering dosage 
thereafter. In two cases only prednisone regimen was increased. Azathioprine was stopped in 
patient 1 and 2; in patient 1 prednisone was reduced from 10 to 7.5 mg/day, while tacrolimus was 
maintained at the same dose.  
Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases, and 
remained within the normal range in all cases except for patient 2 and 4, in whom liver function 
tests dramatically improved. In four hospitalized cases data about lymphocyte count were 
available; all patients experienced acute lymphopenia (severe in two subjects), that was not 
present before admission and fully reverted after COVID-19. 
At the time of submission nine patients are still alive, of whom nine are asymptomatic, and patient 
6 has died. Patient 9, who had previously self-stopped immunosuppression with steroids, has 
experienced a relapse of AIH and is now treated with prednisone 50 mg/day.
Discussion
We report here the first ten cases of COVID-19 occurred in patients with AIH under 
immunosuppressive treatment. With the limitation of the short follow-up and the lack of a control 
group of non-AIH patients, we do report a somehow unremarkable COVID-19 disease course 
despite ongoing immunosuppression. Remarkably, one patient went through COVID-19 without 
developing pneumonia despite the combination of compensated cirrhosis and acute AIH, with 
consequent need for high-dose induction with steroids. The death event occurred in the frailest A
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patient included in the cohort (patient 6), who had already decompensated cirrhosis, which is 
associated with significant morbidity and mortality(7). Moreover, we believe that pre-emptive 
strategies of reduction of immunosuppression during COVID-19 can be potentially harmful, as 
suggested by the disease course of patient 9 that self-stopped steroid treatment and relapsed after 
SARS-CoV-2 infection. There is a growing evidence that part of the morbidity of COVID-19 is 
due to the hyperinflammation and cytokine storm(8), as supported by data from China which 
showed that high levels of IL-6 are associated with increased mortality(9) and the supposed 
beneficial effects of immunomodulators (Tocilizumab and other IL-6 blockers(10), 
Baricitinib(11)). Recently, a systems pharmacology-based network medicine platform identified 
mercaptopurine as one of the potential drugs to treat COVID-19(12). Mercaptopurine, also known 
as 6-mercaptopurine, is a metabolite of Azathioprine, and together with Azathioprine belongs to 
the group of thiopurines, the most commonly used drugs for AIH maintenance. Thus, one could 
speculate that empirical strategies of reduction of immunosuppression in patients affected by 
chronic autoimmune diseases might be even harmful if immunosuppression might at least 
counterbalance COVID-19-driven hyperinflammation. 
One of the known side effects of thiopurines is lymphopenia, which is often mild-to-moderate and 
considered a parameter of effective immunosuppression(13). Yet, lymphopenia is known to 
predispose to viral infections, and thiopurines have been linked with increased incidence of 
opportunistic viral infections in patients with inflammatory bowel disease(4). Data from Wuhan 
experience have clearly shown that most patients with SARS-CoV-2 infection have 
lymphopenia(14), and our data are in line with Chinese findings. The lack of a control group of 
non-AIH patients and the nature of this manuscript (case series) do not allow us to draw 
conclusions regarding the possible association between chronic treatment with thiopurines and the 
risk of developing COVID-19. Whether it would be sensible to stop thiopurines and increase 
steroids in patients with COVID-19 treated with immunosuppression is difficult to be ascertained 
and more evidence is needed. One should consider that it is highly likely that the 
immunosuppressive effect of thiopurines would not immediately cease after drug withdrawal, 
thanks to their mechanism of action(15), while this is probably not true for steroids, as suggested 
by the early relapse occurred in case number 9. Moreover, there is a well-established literature 
showing that patients with AIH in stable control of their disease are at high risk of relapse when 
suddenly reduce/stop their immunosuppression, so that empirical change of immunosuppressive 
medications should be considered with caution(3,16) before more evidence is available.A
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The main limitations of this study are the small sample size and the short follow-up, that prevent 
us to infer whether treated AIH patients have a specific clinical phenotype: to answer this research 
question we would have need a larger sample size and longer observation. In addition, the 
approach toward immunosuppression was too heterogenous to draw solid conclusions, especially 
regarding the beneficial or detrimental role of steroids during COVID-19. Finally, this study does 
not allow to understand whether treated AIH patients are more or less prone to develop COVID-
19, lacking a non-AIH control group. However, since COVID-19 is a rapidly evolving epidemic 
which is affecting countries with a different time fashion, we believe our data are timely and could 
be of value for clinicians.
COVID-19 in patients with AIH treated with immunosuppression seems to have a disease course 
presumptively similar to general population. We believe that empirical reduction of 
immunosuppression in patients with AIH (and, by extension, other autoimmune conditions) during 
COVID-19 might be harmful, since it could expose individuals to a higher risk of relapse of the 
disease(3). Moreover, for most immunosuppressive drugs the immunosuppressant effect would 
take weeks before disappearing. Up to now, a case-by-case approach is warranted, adopting 
clinical judgement until more data are collected and can guide the management of these 
challenging cases.
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ID 1 2 3 4 5 6 7 8 9 10 
Age, y 27 55 45 55 53 68 55 65 68 73 
Sex F M F M F F F M F F 
Cirrhosis yes no no yes yes yes no no no no 
Date of previous 
labs 
17/02/2020 14/02/2020 23/01/2020 09/03/2020 26/09/2019 04/03/2020 01/02/2020 15/03/2020 28/02/2020 20/02/2020 
AST, U/L 21 37 22 317 34 N/A 37 19 50 27 
ALT, U/L 17,4 52 24 497 36 21 19 14 30 16 
T Bil, mg/dl 0,4 1,0 1,0 2,6 1,0 0,9 1,6 0,6 1,0 N/A 
Alb, g/dl 3,9 3,5 4,2 3,0 3,7 N/A 4,3 N/A N/A 3,9 
PLT, ×103/μL 146 255 314 124 177 93 159 N/A N/A 215 
Lymph, x 109/L N/A N/A 2,6 2,5 2,8 N/A N/A 2,1 N/A N/A 
IgG, g/l 14,0 10,0 11,6 33,7 7,8 N/A N/A N/A N/A N/A 
P pre Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Dose (mg) 10 40 10 60 10 5 5 
 
25 20 
AZA pre Yes Yes No No No No Yes No No Yes 
Dose (mg) 50 50 
    
100 
  
75 
Other drugs 
for AIH 
Tac 
 
No No No No No MMF No No 
Dose 1 mg q12h 
      
1500 mg/day 
 
 
Clinical course 
Symptoms onset 07/03/2020 06/03/2020 05/03/2020 17/03/2020 01/03/2020 15/03/2020 18/03/2020 11/03/2020 01/03/2020 27/02/2020 A
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Clinical features 
Cough, 
Headache 
Fever Fever, Cough Fever, Cough 
Cough, Fever, 
Diarrhoea 
Cough, 
Fever 
Cough, 
Fever 
Fever, Cough Fever, Ageusia Fever, Cough 
Swab positive 
for 
SARS-CoV-2? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Managed at 
home or at the 
hospital? 
Home Hospital Hospital Hospital Hospital Hospital Home Hospital Home Home 
Pneumonia? N/A Yes Yes Yes No Yes N/A Yes N/A N/A 
Respiratory 
failure? 
No No Yes No No Yes No Yes No No 
Any change of 
drugs for AIH? 
Yes Yes No Yes Yes Yes No Yes Yes No 
If yes, which 
drug was 
changed? 
P, Aza P, Aza 
 
P P P 
 
MMF P  
Dose change 
P ↓ 7.5 
mg/day, Aza X 
P ↓ 30 
mg/day, Aza X  
P  ↓ 40 
mg/day 
P ↑ 
P ↑ 25 
mg/day  
MMF ↓ 
1000 mg/day 
Self-stopped  
Date of change 15/03/2020 07/03/2020 
 
20/03/2020 10/03/2020 26/03/2020 
 
26/03/20 02/03/2020  
Date of return to 
previous dose 
not yet not yet 
 
not yet 23/03/2020 not yet 
 
not yet 16/05/2020**  
Drugs for Covid-
19 
/ H, L/R, Azi H, L/R H, D/C C, L/R H, L/R / H, L/R, Azi / / A
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Repeated liver 
enzymes during 
COVID-19? 
No* Yes Yes Yes Yes Yes No* Yes No* No* 
AST, U/L 
 
39 23 82 98 34 
 
22 
 
 
ALT, U/L 
 
38 17 101 46 31 
 
11 
 
 
T Bil, mg/dl 
 
1,5 0,9 3,2 1,0 0,8 
 
0,7 
 
 
Alb, g/dl 
 
3,5 3,6 2,6 3,4 N/A 
 
N/A 
 
 
Lymph, x 109/L 
 
N/A 0,7 0,6 0,3 N/A 
 
0,5 
 
 
Follow-up labs 27/04/2020 19/05/2020 20/03/2020 26/03/2020 18/03/2020 No No 01/04/2020 15/05/2020 12/05/2020 
AST, U/L 25 39 30 66 36 
  
27 600 11 
ALT, U/L 34 39 30 89 27 
  
14 599 17 
T Bil, mg/dl 0,6 0,7 N/A 2,2 1 
  
0,4 2,4  
Alb, g/dl 
 
37 N/A N/A 34 
    
39 
Lymph, x 109/L 1,6 3,5 1,5 3,9 1,6 
  
1,0 1,4  
Current status 
(at 21/05/2020) 
A A A A A 
Exitus on 1st 
April 2020 
A A A A 
Table. Clinical course and laboratory results 
 
Abbreviations 
Y, years; F, female; M, male; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T Bil, total bilirubin; PLT, platelets; IgG, 
Immunoglobulin G; Lymph, lymphocytes; P, prednisone; Aza, azathioprine; N/A, not applicable; AIH, autoimmune hepatitis; MMF, A
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mycophenolate; TAC, tacrolimus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; H, hydrochloroquine; L/R, lopinavir/ritonavir; 
Azi, azithromycin; D/C, darunavir/cobicistat; C, chloroquine; A, asymptomatic. 
 
SI conversion factors: To convert platelet count to ×109 per liter, multiply by 1. 
 
*Blood exams not repeated due to restrictions related to compulsory quarantine at home. 
**Restarted with Prednisone 50 mg for the treatment of the relapse of AIH.  
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